

## **Trenchant Technologies Capital Portfolio Company GNQ Insilico Provides Corporate Update and Presents Its Digital Twins Platform at Prestigious Quantum Rising Conference.**

VANCOUVER, BC – January 8, 2025 – Trenchant Technologies Capital (CSE: AITT; OTCQB: AITTF; “**Trenchant**” or the “**Company**”) has received a corporate update from its portfolio company, GNQ Insilico (“**GNQ**”), a leading health tech innovator leveraging Artificial Intelligence (“AI”) and Quantum Computing to revolutionize healthcare. GNQ’s mission is to revolutionize personalized medicine through advanced simulation and modeling techniques, while actively researching future quantum computing applications. For more information, visit [www.gnqinsilico.com](http://www.gnqinsilico.com).

GNQ has made significant progress over the past year in developing its innovative platform which creates comprehensive digital representations of individual patients by integrating multiple data streams, including clinical records, multi-omics data, real-time device measurements, and lifestyle information. These autonomous digital twins serve as dynamic, real-time virtual models of patients' health states, that actively participate in improving health and wellness of their physical counterparts. An example of the use of this innovative approach is in simulated drug trials where digital twins act as virtual drug trial patients with highly accurate results which would aid in the efficacy and accuracy of human led drug trials.

"Our agentic system approach to autonomous digital twins represents a fundamental shift in personalized medicine," said Saxena. "By leveraging advanced AI and machine learning capabilities, we are able to simulate drug responses and predict treatment outcomes with remarkable accuracy from our virtual patient models. Additionally, we are actively exploring how emerging quantum computing technologies could further enhance these capabilities in the future”.

GNQ’s Chief Technology Officer, Sudhir Saxena, was invited by Deloitte to present GNQ’s multi-omics approach to personalized medicine through AI-powered digital twins at the Quantum Rising conference recently held in Atlanta, Georgia and hosted by the National Quantum Literacy Network. At the Quantum Rising conference, Saxena was a speaker on a panel that included Deloitte Consulting and IBM Quantum. He highlighted GNQ's advanced human digital twins and the agentic AI driven platform to enable precision medicine and democratize healthcare. He also elaborated on possibilities of leveraging quantum computing in modeling whole systems biology to further enhance the platform capabilities in personalizing medicine across diverse population segments.

GNQ’s presentation at the Quantum Rising conference demonstrates GNQ’s commitment to advancing personalized medicine through cutting-edge technology. The current integration of agentic AI with digital twin technology, combined with strategic research into quantum computing applications, represents a comprehensive approach to advancing

healthcare, offering new possibilities for personalized treatment approaches and drug development.

### **ABOUT GNQ INSILICO**

GNQ Insilico is at the forefront of developing innovative healthcare solutions that combine digital twin technology with advanced AI capabilities in modeling the whole systems biology. The company's mission is to revolutionize personalized medicine through advanced simulation and modeling techniques, while actively researching future quantum computing applications. This dual focus ensures delivery of current solutions while preparing for future technological advances in healthcare. For more information, visit [www.gnqinsilico.com](http://www.gnqinsilico.com).

### **ABOUT TRENCHANT TECHNOLOGIES CAPITAL (CSE: AITT; OTCQB: AITTF; FSE: A40CR2)**

Trenchant Technologies Capital (CSE: AITT) is an investment issuer focused primarily on seeking investment in companies introducing novel technologies, including Artificial Intelligence and Quantum Computing, to traditional business models that are due for disruption.

Trenchant's team undergoes a rigorous due diligence process to identify companies led by seasoned management teams that are strong candidates for acquisition or an initial public offering (IPO). In May 2024, Trenchant Technologies Capital acquired a 20% ownership interest in GNQ Insilico from parent company My Next Health Inc. Further, Trenchant holds an option to acquire up to 40% of GNQ.

### **ON BEHALF OF THE BOARD TRENCHANT CAPITAL CORP.**

Per: "Eric Boehnke" Eric Boehnke, CEO

For further information, please contact:

Trenchant Technologies Capital Corp. Eric Boehnke, CEO

Phone: (604) 307-4274

### **Forward-Looking Statements**

This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements, including but not limited to GNQ's ability to successfully complete all necessary trials and regulatory approval processes necessary to be in a position to commercialize any of its technologies, including but not limited to its proprietary genomics driven platform are only predictions. Various assumptions were used in drawing the

conclusions or making the predictions contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management of GNQ at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Trenchant Capital and GNQ are under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this news release.